Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

313.13 +1.07 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 703,795
Open 312.13
Bid (Size) 300.11 (1)
Ask (Size) 329.18 (2)
Prev. Close 312.06
Today's Range 310.61 - 314.24
52wk Range 266.98 - 417.81
Shares Outstanding 44,891,523
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Prime Value Investment with Strong Fundamentals and Undervalued Potential
UNITED THERAPEUTICS CORP (UTHR) is a strong value investing pick with low P/E ratios, zero debt, and high profitability, trading below its true worth. Ideal for investors seeking undervalued biotech... 
Via Chartmill
UTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive Uncertainty
Biotechnology company United Therapeutics (NASDAQ:UTHR) missed Wall Street’s revenue expectations in Q2 CY2025, but sales rose 11.7% year on year to $798.6 million. Its non-GAAP profit of $6.41 per... 
Via StockStory

Performance

YTD
-13.1%
-13.1%
1 Month
+5.0%
+5.0%
3 Month
+2.5%
+2.5%
6 Month
-15.5%
-15.5%
1 Year
-3.1%
-3.1%

More News

Read More
Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It
Via Investor's Business Daily
Topics Intellectual Property
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Excels as a High-Quality Pick in the Caviar Cruise Stock Screen
Via Chartmill
Earnings Scheduled For July 30, 2025
Via Benzinga
Preview: United Therapeutics's Earnings
Via Benzinga
Why UNITED THERAPEUTICS CORP (NASDAQ:UTHR) Fits Peter Lynch’s Growth at a Reasonable Price (GARP) Strategy
Via Chartmill
Joby Aviation Soars Amidst eVTOL Hype, Signaling a New Era for Air Mobility
Via MarketMinute
Topics Economy Emissions
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
From United Therapeutics Corporation
Via Business Wire
Forecasting The Future: 8 Analyst Projections For United Therapeutics
Via Benzinga
Earnings Summary on United Therapeutics
Via The Motley Fool
Topics Intellectual Property
United Therapeutics Stock Slides On Q2 Earnings: The Details
Via Benzinga
United Therapeutics (NASDAQ:UTHR) Misses Q2 Revenue Estimates
Via StockStory
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
From United Therapeutics Corporation
Via Business Wire
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings
Via StockStory
Topics Artificial Intelligence
Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work?
Via Investor's Business Daily
UNITED THERAPEUTICS CORP (NASDAQ:UTHR): A Prime Value Pick with Strong Fundamentals and Undervalued Potential
Via Chartmill
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest
Via StockStory
Topics Artificial Intelligence
United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
From United Therapeutics Corporation
Via Business Wire
Q1 Earnings Roundup: Gilead Sciences (NASDAQ:GILD) And The Rest Of The Therapeutics Segment
Via StockStory
Topics Artificial Intelligence
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA)
Via StockStory
Topics Artificial Intelligence
1 Cash-Producing Stock with Impressive Fundamentals and 2 to Keep Off Your Radar
Via StockStory
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks
Via StockStory
Topics Artificial Intelligence
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) – A Strong Candidate for GARP Investors
Via Chartmill
1 Value Stock with Impressive Fundamentals and 2 to Turn Down
Via StockStory

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?
Yes, United Therapeutics Corporation - Common Stock is publicly traded.
What exchange does United Therapeutics Corporation - Common Stock trade on?
United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for United Therapeutics Corporation - Common Stock?
The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market
What is the current price of United Therapeutics Corporation - Common Stock?
The current price of United Therapeutics Corporation - Common Stock is 313.13
When was United Therapeutics Corporation - Common Stock last traded?
The last trade of United Therapeutics Corporation - Common Stock was at 08/15/25 04:00 PM ET
What is the market capitalization of United Therapeutics Corporation - Common Stock?
The market capitalization of United Therapeutics Corporation - Common Stock is 14.06B
How many shares of United Therapeutics Corporation - Common Stock are outstanding?
United Therapeutics Corporation - Common Stock has 14B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.